eye problems with semaglutide Ozempic Blindness: Should You Worry? Ophthalmologic Manifestations from Semaglutide (Ozempic/Wegovy)

The analysis focused on adults aged 18 years and older with type 2 diabetes mellitus who initiated one of the following treatments between December 2018 and December 2021: Semaglutide Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) Other glucose-lowering therapies Participants were followed through to December 2023

In my personal experience, I haven't encountered any significant negative side effects

Regulations: Most countries have not approved it as a drug and it is for research purposes

For example, efpeglenatide, a long-acting GLP-1 RA and an exendin analog linked to an IgG4 Fc fragment, has been explored for once-monthly administration to treat type 2 diabetes.197,198 Additionally, efforts have been made to develop oral formulations with improved bioavailability ( F )